Clinical Trial: ctDNA-MRD Monitoring for Stage I-III Resectable Colon Adenocarcinoma With Oncogenic Driver Mutations: A Multicenter Prospective Cohort Study

U.S., Sept. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07795528) titled 'ctDNA-MRD Monitoring for Stage I-III Resectable Colon Adenocarcinoma With Oncogenic Driver Mutations: A Multicenter Prospective Cohort Study' on Aug. 23.

Brief Summary: This is a multicenter, prospective, observational cohort study enrolling 392 patients with stage I-III radically resectable colon adenocarcinoma carrying at least one oncogenic driver mutation (KRAS, NRAS, BRAF, PIK3CA). Serial plasma ctDNA-MRD testing via a standardized 10-gene NGS panel will be performed at predefined time points during 3-year postoperative follow-up. The primary objective is to evaluate the correlation between postoperative ctDNA-MRD status and re...